ReviewCochrane evidence synthesis and methods2024
Analysis of Cochrane systematic reviews: A comprehensive study of impact and influence from 1998 to 2024.
Review in Cochrane evidence synthesis and methods, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Current Situation and Future Trends of Ergothioneine in Biology and Medical Research: A Bibliometric Analysis.Journal of multidisciplinary healthcare · 2025Review
- Analysis of Cochrane systematic reviews: A comprehensive study of impact and influence from 1998 to 2024.Cochrane evidence synthesis and methods · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Evidence from Cochrane systematic reviews has significantly impacted clinical practices across diverse disciplines and is widely integrated into international guidelines. To date, there are no bibliometric analyses of Cochrane's publications. Methods: The search encompassed the Scopus database from inception to May 2024, with results limited to studies published by the Cochrane Database of Systematic Reviews. The analysis examined annual trends and publication volumes, citation patterns, contributing countries, authors, institutions, funding sources, and common keywords. Scopus' built-in analytical tools, the bibliometrix package in RStudio, and VOSviewer software facilitated the analysis of the results. Results: A total of 12,150 systematic reviews were eligible. There was a fluctuating pattern in publication and citation trends within Cochrane reviews, with a decline in both metrics since 2016. Contributions mainly came from high-income countries, their institutions, and authors residing there, with significant government funding supporting publications in these regions. The United Kingdom (27%), Australia (10%), and the United States (9%) had the greatest contributions among other countries, respectively. Furthermore, the demographic emphasis in Cochrane reviews was concerned with female and male participants as well as children and adult populations, hinting at the potential underrepresentation of minor gender identities and older adults in the synthesis of evidence. Conclusion: Cochrane should actively involve researchers and experts from low- and middle-income countries in evidence synthesis, ensure underrepresented and low-resource regions are included in its emerging Evidence Synthesis Units and Thematic Groups, and prioritize the inclusion of geriatric populations and sexual and gender minorities in its evidence to enhance inclusivity and global representation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.